3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
5
Phase 2
4
Phase 2/3
2
Phase 1/2
2
Phase 1
2
Phase 3
1
Status
Unknown
1
Suspended
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Carcinoma, Hepatocellular
5
Liver Neoplasms
2
Uterine Cervical Neoplasms
1
Neoplasms
1
Hepatoblastoma
1
Hepatitis B
1
Advanced Non-small Cell Lung Cancer
1
Interventions
Sorafenib
3
lenvatinib
2
sintilimab
1
pembrolizumab
1
halofantrine
1
glucose-regulated proteins
1
camrelizumab
1
Tranexamic Acid
1
Thalidomide
1
Sunitinib
1
Standard of Care
1
Saline Solution
1
Oxaliplatin
1
Nadroparin
1
Lidocaine
1
Injections
1
Immune Checkpoint Inhibitors
1
Heparin, Low-Molecular-Weight
1
Gemcitabine
1
Folfox protocol
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Liver Neoplasms
×
lenvatinib
×
Clear all
NCT05033522
2025-10-23
ALIVE
Mirror Biologics, Inc.
Phase 2/3
Suspended
150 enrolled
NCT05322187
2022-04-11
sPLENTY-pc
RenJi Hospital
Phase 2/3
Unknown
15 enrolled